{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:30:08Z","timestamp":1780626608334,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.eplepsyres.2021.106697","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T04:51:58Z","timestamp":1624423918000},"page":"106697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Factors associated with blood carnitine levels in adult epilepsy patients with chronic valproic acid therapy"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-8366","authenticated-orcid":false,"given":"Masanori","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Miyaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2021.106697_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000448320","article-title":"Historical perspective on clinical trials of carnitine in children and adults","volume":"68","author":"Buist","year":"2016","journal-title":"Ann. Nutr. Metab."},{"issue":"39","key":"10.1016\/j.eplepsyres.2021.106697_bib0010","first-page":"e8117","article-title":"Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: essential review of the literature and case report","volume":"96","author":"Cattaneo","year":"2017","journal-title":"Bull. Sch. Med. Md"},{"key":"10.1016\/j.eplepsyres.2021.106697_bib0015","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s11136-004-1260-6","article-title":"Methodological issues in determining the dimensionality of composite health measures using principal component analysis: case illustration and suggestions for practice","volume":"14","author":"Coste","year":"2005","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.eplepsyres.2021.106697_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2015.09.004","article-title":"Disorders of carnitine biosynthesis and transport","volume":"116","author":"El-Hattab","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.eplepsyres.2021.106697_bib0025","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003088-200342110-00002","article-title":"Pharmacokinetics of L-Carnitine","volume":"42","author":"Evans","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2021.106697_bib0030","series-title":"Primer of Applied Regression and Analysis of Variance","first-page":"219","article-title":"Using principal components to diagnose and treat multicollinearity","author":"Glantz","year":"2001"},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106697_bib0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1528-1157.1977.tb04462.x","article-title":"Valproate sodium: a controlled clinical trial including monitoring of drug levels","volume":"18","author":"Gram","year":"1977","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2021.106697_bib0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00007691-198507030-00009","article-title":"Chronic valproic acid therapy and incidence of increases in venous plasma ammonia","volume":"7","author":"Haidukewych","year":"1985","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106697_bib0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3476(05)80306-3","article-title":"Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children","volume":"119","author":"Hug","year":"1991","journal-title":"J. Pediatr."},{"key":"10.1016\/j.eplepsyres.2021.106697_bib0050","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.V133708","article-title":"Effects of L-Carnitine supplementation in maintenance hemodialysis patients: a systematic review","volume":"13","author":"Hurot","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2021.106697_bib0055","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1248\/bpb.35.971","article-title":"Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy","volume":"35","author":"Itoh","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106697_bib0060","first-page":"345","article-title":"L-carnitine: therapeutic applications of a conditionally-essential amino acid","volume":"3","author":"Kelly","year":"1998","journal-title":"Altern. Med. Rev."},{"issue":"1","key":"10.1016\/j.eplepsyres.2021.106697_bib0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-3476(86)80592-3","article-title":"Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy","volume":"109","author":"Matsuda","year":"1986","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.eplepsyres.2021.106697_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2146\/ajhp110049","article-title":"Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy","volume":"69","author":"Mock","year":"2012","journal-title":"Am. J. Health. Syst. Pharm."},{"issue":"8","key":"10.1016\/j.eplepsyres.2021.106697_bib0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2957\/kanzo.59.421","article-title":"A case of valproate-induced hyperammonemia due to carnitine deficiency who responded well to levocarnitine therapy","volume":"59","author":"Nozu","year":"2018","journal-title":"Kanzo."},{"key":"10.1016\/j.eplepsyres.2021.106697_bib0080","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.braindev.2019.02.010","article-title":"Serum carnitine levels of children with epilepsy: related factors including valproate","volume":"41","author":"Okumura","year":"2019","journal-title":"Brain Dev."},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106697_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2472555218812821","article-title":"OCTN: a small transporter subfamily with great relevance to human pathophysiology, drug discovery, and diagnostics","volume":"24","author":"Pochini","year":"2019","journal-title":"SLAS Discov."},{"key":"10.1016\/j.eplepsyres.2021.106697_bib0090","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jocn.2013.04.033","article-title":"Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine","volume":"21","author":"Rigamonti","year":"2014","journal-title":"J. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106697_bib0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0009-8981(89)90185-X","article-title":"Carnitine deficiency associated with anticonvulsant therapy","volume":"181","author":"Rodriguez-Segade","year":"1989","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106697_bib0100","first-page":"15","article-title":"Methods for the detection of carnitine in human serum","volume":"16","author":"Tsushima","year":"2000","journal-title":"Jpn. J. Clin. Dialysis."},{"issue":"7","key":"10.1016\/j.eplepsyres.2021.106697_bib0105","first-page":"767","article-title":"The Study of Analytical Performance and Clinical Usefulness of the Total Carnitine and Free Carnitine Measurement Reagents","volume":"65","author":"Umemori","year":"2017","journal-title":"Of. J. Jpn. Soc. Lab. Med."},{"issue":"6","key":"10.1016\/j.eplepsyres.2021.106697_bib0110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpedi.1987.04460060076039","article-title":"Plasma carnitine deficiency: clinical observations in 51 pediatric patients","volume":"141","author":"Winter","year":"1987","journal-title":"Am J Dis Child."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:46:14Z","timestamp":1760276774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121121001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":22,"alternative-id":["S0920121121001509"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106697","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with blood carnitine levels in adult epilepsy patients with chronic valproic acid therapy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106697"}}